Bio-Techne: Matthew McManus

Bio-Techne has appointed Matthew McManus as president of its diagnostics and genomics segment, effective Jan. 8. He is replacing Kim Kelderman, who is taking over as Bio-Techne's CEO on Feb. 1. McManus was previously SVP and general manager of Bio-Techne's molecular diagnostics division after its acquisition of Asuragen, where he was president and CEO. He most recently served as EVP and COO for life sciences firm Azenta. McManus is also currently chairman of the board of directors for gene synthesis and cell and gene therapy company Ansa.